Advertisement

Loading...

Helix BioPharma Corp.

HBP.TOTSX
Healthcare
Biotechnology
$1.85
$-0.09(-4.64%)
Canadian Market is Open • 14:20

Helix BioPharma Corp. (HBP.TO) Stock Competitors & Peer Comparison

See (HBP.TO) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HBP.TOCA$1.84+0.00%140.5M-30.67-CA$0.06N/A
BLU.TOCA$19.48-0.10%2.5B-20.29-CA$0.96N/A
MMED.NECA$14.90+9.48%1.1B-4.50-CA$3.31N/A
DRUG.CNCA$97.11-4.16%753.7M-35.18-CA$2.76N/A
EPRX.TOCA$9.31-1.38%334.6M-6.56-CA$1.42N/A
FRX.TOCA$8.33-4.25%238.1M-17.35-CA$0.48N/A
CYBN.NECA$6.28-3.68%153M-1.22-CA$5.17N/A
ONC.TOCA$1.42+2.16%142.3M-3.84-CA$0.37N/A
MSCL.TOCA$8.61-10.31%133.1M2.43CA$3.54N/A
MSET.CNCA$0.74-1.33%75M-12.33-CA$0.06N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HBP.TO vs BLU.TO Comparison April 2026

HBP.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HBP.TO stands at 140.5M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, HBP.TO is priced at CA$1.84, while BLU.TO trades at CA$19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HBP.TO currently has a P/E ratio of -30.67, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, HBP.TO's ROE is -0.37%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, HBP.TO is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for HBP.TO.Check BLU.TO's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions